TRU-SENTIMENT · DeltaNeutral
TXG Trading Analysis - 10/29/2026 10:24 AM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
TXG (10x Genomics Inc. Class A Common Stock) at $83.66. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $2,760 vs put $0. RSI 57.5.
- Symbol
- TXG
- Price
- $83.66
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-10-29 10:24:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow via True Sentiment (Delta 40-60 only):
Call Volume: $2,760.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $2,760.00
Sentiment is Bullish with 3 call contracts, 0 puts, 2 call trades. Pure directional conviction is entirely bullish but on very low sample (2 of 244 options analyzed, 0.80% filter). Near-term expectations: tentative upside bias, no bearish hedge. Divergence: technical SMA stack is irregular and fundamentals negative, yet options show 100% call conviction — small-size optimism not confirmed by broader data.
Key Statistics: TXG
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-0.59 |
| Market cap | $10.78B |
| Shares outstanding | 130.3M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.72 |
| 52-week low | $12.34 |
| 52-week high | $102.81 |
| Historical volatility | 92.2% |
Ownership & trading
| Institutional ownership | 76.5% |
| Average daily volume | 4.0M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Recent general-knowledge headlines and context for 10x Genomics (TXG) that may frame the data below:
- 10x Genomics announced new single-cell RNA-seq instrument upgrades aimed at improving lab throughput, potentially supporting longer-term adoption.
- Company reported a prior-quarter operating loss with negative EPS, consistent with its early-profitability biotech profile and high cash-burn risk.
- Broader genomics-tools demand showed uneven academic spending, a recurring catalyst that can pressure TXG revenue visibility.
- No confirmed near-term earnings date in provided data; fiscal year end listed as 2025-12-01, suggesting seasonal fundamental updates may be stale.
- Headlines lean cautiously constructive on product cycle but do not offset the negative EPS and high-beta volatility seen in the embedded fundamentals and technicals.
Context: News of product upgrades contrasts with the negative trailing EPS (-0.59) and elevated historical volatility (92.21%) in the data, while the bullish delta-40-60 options flow suggests tactical optimism not yet backed by fundamental profitability.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for TXG:
- Trailing EPS is -0.59; company is not profitable on a trailing basis (trailingPE null, forwardPE null).
- Revenue growth, gross/operating/net margins, ROE, and profit margins are null in the data — not available for trend analysis.
- P/E and PEG ratio are null; valuation cannot be compared via multiples, only via price-to-book (null) and market cap of $10,778,974,430.00.
- Debt/equity, free cash flow, and target mean price are null; analyst consensus and recommendations are null.
- Strengths: Institutional ownership is 76.51%, average volume 4,040,000, and 52-week range of $12.34 to $102.81 shows extreme recovery potential.
- Concerns: Beta 1.72 and historical volatility 92.21% imply high systematic risk; negative EPS and missing profitability metrics diverge from the bullish technical and options flow.
Fundamentals show a pre-profit biotech with high institutional interest but no earnings support, diverging from the bullish technical and sentiment reads in the embedded data.
Current Market Position
Current price per indicators is $83.95 (2026-10-28 close $83.95). Recent daily action: 2026-10-28 opened $78.93, high $87.82, low $78.25, close $83.95 on volume 4,100,292 — a strong rebound from $78.31 on 2026-10-27. Minute bars show 2026-10-28 09:30 at $79.90 climbing to $84.31 by 09:50, and 2026-10-29 09:55 at $83.66 after intraday range $83.05–$84.40, indicating stabilizing momentum near $83.50–$84.00.
Technical Analysis
Technical Indicators
SMA alignment: 5-day $74.84 < 20-day $77.55 < 50-day $73.67 is irregular; price $83.95 is above all three, showing short-term strength but no clean bullish stack (50-day below 20-day). RSI 57.45 is moderate-positive, not overbought. MACD histogram +0.03 (macd 0.17 > signal 0.14) is marginally bullish. Bollinger: middle $77.55, upper $93.51, lower $61.60 — price near upper-third, no squeeze (wide bands). 30-day range high $102.81 / low $67.25; current $83.95 is ~50% up the range, below midpoint-retrace from high.
True Sentiment Analysis (Delta 40-60 Options)
Options flow via True Sentiment (Delta 40-60 only):
Call Volume: $2,760.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $2,760.00
Sentiment is Bullish with 3 call contracts, 0 puts, 2 call trades. Pure directional conviction is entirely bullish but on very low sample (2 of 244 options analyzed, 0.80% filter). Near-term expectations: tentative upside bias, no bearish hedge. Divergence: technical SMA stack is irregular and fundamentals negative, yet options show 100% call conviction — small-size optimism not confirmed by broader data.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.